Skip to content

The effect of oral carnitine supplement in apnea of prematurity in the NICU of sums related hospitals

The effect of oral carnitine supplement in apnea of prematurity in the NICU of sums related hospitals

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013052010441N2
Enrollment
112
Registered
2013-06-28
Start date
2012-08-10
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Apnea in preterm infants. Other apnoea of newborn

Interventions

Intervention 1: intervention:Neonates were randomly assigned to receive oral carnnitine (100mg/kg/day) divided in q12hr,that were initiated within 72 hours of birth and recording episods of apnea
Treatment - Drugs
intervention:Neonates were randomly assigned to receive oral carnnitine (100mg/kg/day) divided in q12hr,that were initiated within 72 hours of birth and recording episods of apnea and bradycardia
in control group: receive oral placebo ( with the same amount in volume) initiated within 72 hours of birth and recording of apnea episods q8hr . finally interpreting the result

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 15 Years

Inclusion criteria

Inclusion criteria: Inclusion criterion: all newborn infants who have a gestational age of =32 week or have birth weight of=1500 gr. Exclusion criteria: any neonate with sever congenital anomalies; genetic and chromosomal abnormalities; inborn error of metabolism; severe IVH; sever liver disease and sepsis.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Apnea in preterm infants. Timepoint: 2 days to 2 weeks. Method of measurement: monitoring.

Secondary

MeasureTime frame
Episodes of apnea and growth indices in the infants. Timepoint: 2 days to 2 weeks. Method of measurement: Monitoring.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Bolod Soleimani

Shiraz University of Medical Sciences

soleimani_b@sums.ac.ir+98 71 1612 5481

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026